INTRODUCTION
COVID-19 has been associated with venous and arterial thromboembolic
disease likely due to potent local and systemic cytokine production with
subsequent platelet activation, thrombin stimulation, and fibrin
deposition [1]. Such thromboembolic disease is treated with
anticoagulation but there are no guidelines to direct the types and
duration of oral anticoagulation. We present a case of COVID-associated
acute coronary syndrome (ACS) and left ventricular thrombi with
resolution of the thrombi within 2 months of warfarin initiation.